WO2007107706A3 - Multimeres de composes heterocycliques et leur utilisation - Google Patents

Multimeres de composes heterocycliques et leur utilisation Download PDF

Info

Publication number
WO2007107706A3
WO2007107706A3 PCT/GB2007/000919 GB2007000919W WO2007107706A3 WO 2007107706 A3 WO2007107706 A3 WO 2007107706A3 GB 2007000919 W GB2007000919 W GB 2007000919W WO 2007107706 A3 WO2007107706 A3 WO 2007107706A3
Authority
WO
WIPO (PCT)
Prior art keywords
dimers
treatment
copd
heterocyclic compounds
compounds
Prior art date
Application number
PCT/GB2007/000919
Other languages
English (en)
Other versions
WO2007107706A2 (fr
Inventor
Harry Finch
Christine Edwards
Nicholas Charles Ray
Original Assignee
Argenta Discovery Ltd
Harry Finch
Christine Edwards
Nicholas Charles Ray
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Argenta Discovery Ltd, Harry Finch, Christine Edwards, Nicholas Charles Ray filed Critical Argenta Discovery Ltd
Publication of WO2007107706A2 publication Critical patent/WO2007107706A2/fr
Publication of WO2007107706A3 publication Critical patent/WO2007107706A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des conjugués covalents de deux composés ou plus, chacun doté d'une structure telle que définie dans l'un des documents WO2004/043924, WO2005/021509, WO2005/021512, WO2005/026123, WO2005/026124, WO2006/098683 et WO2006/098684. Lesdits conjugués sont des inhibiteurs de l'élastase neutrophile humaine et sont notamment utiles dans le traitement de la bronchopneumopathie chronique obstructive. L'invention concerne des dimères de formule (IA) ou (IB): dans lesquelles le LIEUR et les substituants variables sont des types particuliers desdits multimères.
PCT/GB2007/000919 2006-03-17 2007-03-16 Multimeres de composes heterocycliques et leur utilisation WO2007107706A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605469.6A GB0605469D0 (en) 2006-03-17 2006-03-17 Multimers of heterocyclic compounds and their use
GB0605469.6 2006-03-17

Publications (2)

Publication Number Publication Date
WO2007107706A2 WO2007107706A2 (fr) 2007-09-27
WO2007107706A3 true WO2007107706A3 (fr) 2008-10-09

Family

ID=36293016

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/000919 WO2007107706A2 (fr) 2006-03-17 2007-03-16 Multimeres de composes heterocycliques et leur utilisation

Country Status (2)

Country Link
GB (1) GB0605469D0 (fr)
WO (1) WO2007107706A2 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
EP2064184A1 (fr) * 2006-09-04 2009-06-03 AstraZeneca AB Composés hétérocycliques multimériques utilisés comme inhibiteurs de l'élastase neutrophile
WO2009037413A1 (fr) * 2007-09-19 2009-03-26 Argenta Discovery Limited Dimères de 5-[(4-cyanophényl)sulfinyl]-6-méthyl-2-oxo-1-[3-(trifluorométhyl)phényl]-1,2-dihydropyridine-3-carboxamide en tant qu'inhibiteurs de l'élastase des neutrophiles humains pour traiter des maladies respiratoires
CL2008003301A1 (es) 2007-11-06 2009-10-16 Astrazeneca Ab Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras.
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
WO2011039528A1 (fr) * 2009-10-02 2011-04-07 Astrazeneca Ab Composés 2-pyridones utilisés comme inhibiteurs d'élastase de neutrophile
CN105518000B (zh) 2013-07-02 2018-09-14 加州生物医学研究所 用于治疗囊性纤维化的化合物
US9221807B2 (en) * 2014-02-21 2015-12-29 Boehringer Ingelheim International Gmbh Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity
WO2015179823A2 (fr) * 2014-05-23 2015-11-26 The California Institute For Biomedical Research Inhibiteurs d'alpha (v) bêta 6, localisés dans les poumons
US9487528B2 (en) * 2014-06-09 2016-11-08 Chiesi Farmaceutici S.P.A. Compounds
WO2015188866A1 (fr) * 2014-06-12 2015-12-17 Chiesi Farmaceutici S.P.A. Nouveaux composés
WO2015200349A2 (fr) * 2014-06-24 2015-12-30 The California Institute For Biomedical Research Inhibiteurs de l'élastase
CN107405505A (zh) * 2015-01-07 2017-11-28 加州生物医学研究所 用于治疗囊性纤维化的化合物
US9802919B1 (en) * 2016-05-31 2017-10-31 Chiesi Farmaceutici S.P.A. Compounds
CN114650819A (zh) 2019-09-17 2022-06-21 美莱奥生物制药第四有限公司 用于治疗移植物排斥、闭塞性细支气管炎综合征和移植物抗宿主病的阿维来司他
IL297211A (en) 2020-04-16 2022-12-01 Mereo Biopharma 4 Ltd Methods involving the neutrophil elastase inhibitor albalstat for the treatment of respiratory disease mediated by alpha-1 antitrypsin deficiency
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043924A1 (fr) * 2002-11-12 2004-05-27 Astrazeneca Ab Derives de 2-pyridone en tant qu'inhibiteurs de l'elastase de neutrophile
WO2005021512A1 (fr) * 2003-08-28 2005-03-10 Astrazeneca Ab Derives de quinoxaline utilises comme inhibiteurs de l'elastase neutrophile et leur utilisation
WO2005021509A1 (fr) * 2003-08-28 2005-03-10 Astrazeneca Ab Derives de quinoline utilises comme inhibiteurs de l'elastase neutrophile et utilisation de ces derives
WO2005026123A1 (fr) * 2003-09-18 2005-03-24 Astrazeneca Ab Derives de 2-pyridone utilises en tant q'inhibiteurs de l'elastase neutrophile et utilisations de ceux-ci
WO2005026124A1 (fr) * 2003-09-18 2005-03-24 Astrazeneca Ab Derives 2-pyridone utilises comme inhibiteurs d'elastase neutrophile et utilisation de ceux-ci
WO2008030158A1 (fr) * 2006-09-04 2008-03-13 Astrazeneca Ab Composés hétérocycliques multimériques utilisés comme inhibiteurs de l'élastase neutrophile

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043924A1 (fr) * 2002-11-12 2004-05-27 Astrazeneca Ab Derives de 2-pyridone en tant qu'inhibiteurs de l'elastase de neutrophile
WO2005021512A1 (fr) * 2003-08-28 2005-03-10 Astrazeneca Ab Derives de quinoxaline utilises comme inhibiteurs de l'elastase neutrophile et leur utilisation
WO2005021509A1 (fr) * 2003-08-28 2005-03-10 Astrazeneca Ab Derives de quinoline utilises comme inhibiteurs de l'elastase neutrophile et utilisation de ces derives
WO2005026123A1 (fr) * 2003-09-18 2005-03-24 Astrazeneca Ab Derives de 2-pyridone utilises en tant q'inhibiteurs de l'elastase neutrophile et utilisations de ceux-ci
WO2005026124A1 (fr) * 2003-09-18 2005-03-24 Astrazeneca Ab Derives 2-pyridone utilises comme inhibiteurs d'elastase neutrophile et utilisation de ceux-ci
WO2008030158A1 (fr) * 2006-09-04 2008-03-13 Astrazeneca Ab Composés hétérocycliques multimériques utilisés comme inhibiteurs de l'élastase neutrophile

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAN YI FAN ET AL: "Dual-site binding of bivalent 4-aminopyridine- and 4-aminoquinoline-based AChE inhibitors: contribution of the hydrophobic alkylene tether to monomer and dimer affinities", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER SCIENCE LTD, GB, vol. 7, no. 11, 1 January 1999 (1999-01-01), pages 2569 - 2575, XP002365936, ISSN: 0968-0896 *

Also Published As

Publication number Publication date
GB0605469D0 (en) 2006-04-26
WO2007107706A2 (fr) 2007-09-27

Similar Documents

Publication Publication Date Title
WO2007107706A3 (fr) Multimeres de composes heterocycliques et leur utilisation
IL250847A0 (en) 5-substituted quinazolinone derivatives as anticancer agents
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2007087395A3 (fr) INHIBITEURS DE mTOR INSATURES
WO2008024978A3 (fr) Dérivés de benzène, de pyridine et de pyridazine
EP2057158B8 (fr) Dérivés de triazole en tant qu'inhibiteurs de kinase
WO2009036092A9 (fr) Agents antitumoraux ciblant les mitochondries
DE602007003074D1 (de) Neue pyrinderivate
PT2044036E (pt) Derivados de [4,5′]bipirimidinil-6,4′-diamina como inibidores de proteína quinase
WO2010038086A3 (fr) Nouveaux composés
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
WO2008048867A3 (fr) Composés hétoroaromatiques bicycliques
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
WO2007143434A3 (fr) Activateurs de glucokinase
MX2009009774A (es) Derivados de quinolina como fungicidas.
WO2009087098A3 (fr) Fongicides
WO2008053194A3 (fr) Composés chimiques
WO2010058032A3 (fr) Nouveaux composés
WO2007115620A3 (fr) Nouveaux composés de cyclobutyle en tant qu'inhibiteurs de kinase
WO2008001195A3 (fr) Nouveaux procédés de synthèse d'inhibiteurs de dpp iv
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
WO2008152014A3 (fr) Nouveaux composés
WO2007097981A3 (fr) Alpha carbolines et leurs utilisations
WO2008008700A3 (fr) Composés thérapeutiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07712911

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07712911

Country of ref document: EP

Kind code of ref document: A2